RIPK2 and experimental autoimmune encephalomyelitis: WEHI-345, which was identified as a RIPK2 inhibitor by screening a proprietary library of 120 kinase inhibitors, delayed NF-κB activation by inhibiting polyubiquitination of RIPK2 and ameliorated experimental autoimmune encephalomyelitis (Nachbur et al., 2015).